QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy
暂无分享,去创建一个
R. Berecz | A. Llerena | P. Dorado | A. Rubia
[1] W A Ray,et al. Antipsychotics and the risk of sudden cardiac death. , 2001, Archives of general psychiatry.
[2] A H Glassman,et al. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.
[3] C Antzelevitch,et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.
[4] A. Camm,et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.
[5] S. Ayis,et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.
[6] B. Phibbs,et al. Torsade de pointes and low-dose oral haloperidol. , 1997, Archives of internal medicine.
[7] T. Stern,et al. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. , 1995, Psychosomatics.
[8] C. Alm,et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. , 1992, Therapeutic drug monitoring.
[9] J. Vandenbroucke,et al. QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population , 1991, Circulation.
[10] A. Llerena,et al. Debrisoquin oxidation polymorphism in a Spanish population , 1988, Clinical pharmacology and therapeutics.
[11] S. Dahl,et al. Clinical Pharmacology in Psychiatry , 1981, Palgrave Macmillan UK.